Comparative Study of the Level of Neutralizing Antibodies in People Injecting 4 Types of COVID-19 Vaccine

Document Type : Original Article (s)

Authors

1 MSc, Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

2 PhD, Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

3 PhD, Isfahan Endocrine and Metabolism Research Centre (IEMRC), School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v42.i765.0333

Abstract

Background: Monitoring the disease of COVID-19 and the effectiveness of prevention and control strategies is considered a public health priority. Therefore, the administration of the COVID-19 vaccine has been approved worldwide. The purpose of this review is to describe the current status and quality of COVID-19 vaccines.
Methods: In this study, the history and sampling of people injecting vaccines with different platforms at different ages in one year were done to measure the neutralizing antibody titer by ELISA method. The results were analyzed using the ANOVA method, and the significance level of P < 0.01 was determined.
Findings: 168 people (109 women and 59 men) with an average age of 40.4 ± 16 years (minimum 18 and maximum 90) participated in the study. The time between vaccination and sampling was 6.7 ± 6.5 (minimum 0.5 and maximum 32) months. Most participants were in the age groups of 21-30 years, and people aged 81-90 were the minimum in the study. No significant relationship between age and antibody response was observed. Sinopharm vaccine had the highest number of injections (80 people), and Barkat vaccine had the lowest number (13 people). Despite significant differences in average antibody levels, all vaccines effectively produced neutralizing antibodies, and high antibody titers could be measured for a long time.
Conclusion: Data on vaccine antibody persistence, including potential booster doses or changes in vaccine formulations, are emphasized. Understanding how these vaccines work in producing protective antibodies is influential in evaluating their effectiveness.

Highlights

Safoora Shirani ShamsAbadi: Google Scholar

Laleh Hoveida: Google Scholar, PubMed

Nafiseh Sadat Naghavi: PubMed

Mojtaba Akbari: PubMed

Keywords

Main Subjects

References

  1. Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Ther Clin Pract 2020; 39: 101132.
  2. Kim JM, Chung YS, Jo HJ, Lee NJ, Kim MS, Woo SH, et al. Identification of coronavirus isolated from a patient in Korea with COVID-19. Osong Public Health Res Perspect 2020; 11(1): 3-7.
  3. Jamalinik M, Haddadi M, Abedi A, Tajabadi A, Ganjloo J, Hasheminik M. COVID-19; Symptoms, transmission methods, care and treatment techniques based on the latest evidence available: A narrative review study [in Persian]. Iran Occupational Health 2020; Special Issue: 17.
  4. Alavian F. A review of the effective approaches to the production of vaccines to prevent the infection COVID-19 [in Persian]. Green Chemistry And Sustainable Technologies 2021; (3)3: 29-30.
  5. van Gils MJ, van Willigen HD, Wynberg E, Han AX, van der Straten K, Burger JA, et al. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Rep Med 2022; 3(1): 100486.
  6. Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Sig Transduct Target Ther 2020; 5(1): 180.
  7. Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun 2021; 12(1): 2670.
  8. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, Hu C, Ourselin S, Steves CJ, Valdes AM, Spector TD. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis 2022; 22(7): 1002-10.
  9. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet infectious diseases. 2021 Jan 1;21(1):39-51.
  10. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microb 2021; 2(9): e423.
Journal of Isfahan Medical School
Volume 42, Issue 765
1st Week, July
July and August 2024
Pages 333-340

Files

History

  • Receive Date: 23 June 2024
  • Accept Date: 29 July 2024

Share

How to cite

Statistics